The European agency that evaluates medicine said Friday it will review the safety of the diabetes drug Avandia following research suggesting it is linked to a higher risk of heart problems, strokes and deaths in older adults.
Original post:
European agency to review safety of GSK’s Avandia
Popular Posts:
- AMCP Review of Health Care Reform Legislation (Part 1)
- Anadys hepatitis C drug meets key study goals
- Summary Box: Lilly halts Alzheimer’s drug
- Medicare Prescription Drug Coverage For Dummies
- Bristol-Myers reports diabetes drug results